1518
Y. Oda et al.
SPECIAL TOPIC
(1c-2F; 66 mg, 0.20 mmol), and 2a (88 mg, 0.60 mmol) in DMF
(2.0 mL) at 65 °C for 8 h. The crude product was purified by column
chromatography on silica gel (hexane–EtOAc, 2:1, v/v) followed by
GPC to give 3ca as a pale pink powder; yield: 44 mg (0.13 mmol,
63%); mp 190–192 °C.
1H NMR (400 MHz, CDCl3): δ = 2.37 (s, 3 H), 7.21 (d, J = 8.2 Hz,
2 H), 7.27–7.34 (m, 2 H), 7.40–7.49 (m, 4 H), 7.60 (d, J = 8.2 Hz,
2 H), 7.87 (d, J = 8.2 Hz, 2 H), 8.38 (d, J = 7.6 Hz, 1 H), 9.22 (br s,
1 H).
1H NMR (400 MHz, CDCl3): δ = 7.11–7.18 (m, 4 H), 7.28–7.40 (m,
4 H), 7.46 (t, J = 7.8 Hz, 1 H), 7.51–7.55 (m, 2 H), 7.66 (d, J = 6.4
Hz, 1 H), 7.74 (d, J = 8.7 Hz, 1 H), 7.94 (d, J = 7.8 Hz, 1 H), 7.99
(d, J = 8.2 Hz, 1 H), 8.52–8.55 (m, 1 H), 9.29 (br s, 1 H).
13C NMR (100 MHz, CDCl3): δ = 100.7, 111.4, 121.7, 122.2,
123.75, 123.79, 125.0, 125.6, 125.8, 126.2, 126.3, 127.0, 128.2,
128.5, 128.6, 129.5, 129.9, 130.8, 132.3, 133.4, 135.9, 138.5, 161.8,
162.4.
HRMS: m/z (M+) calcd for C26H17N3O: 387.1372; found: 387.1375.
13C NMR (100 MHz, CDCl3): δ = 21.4, 97.6, 111.4, 121.4, 122.0,
123.5, 124.2, 126.6, 126.7, 128.5, 128.9, 129.1, 129.2, 131.1, 135.8,
139.5, 140.9, 162.4, 162.8.
2-[2-(tert-Butyl)-1H-indol-3-yl]-5-phenyl-1,3,4-oxadiazole (3ga)
Following the typical procedure for 3aa, the reaction was per-
formed with CuF2 (61 mg, 0.60 mmol), 1,10-phenanthroline (109
mg, 0.60 mmol), K3PO4 (191 mg, 0.90 mmol), MS 3Å (200 mg), N-
[2-(3,3-dimethylbut-1-ynyl)phenyl]methanesulfonamide (1g-Ms;
50 mg, 0.20 mmol), and 2a (88 mg, 0.60 mmol) in DMF (2.0 mL)
at 65 °C for 8 h. The crude product was purified by column chroma-
tography on silica gel (hexane–EtOAc, 2:1, v/v) followed by GPC
to give 3ga as a pale yellow oil; yield: 45 mg (0.14 mmol, 70%).
1H NMR (400 MHz, CDCl3): δ = 1.66 (s, 9 H), 7.24–7.30 (m, 2 H),
7.43 (d, J = 7.3 Hz, 1 H), 7.54–7.55 (m, 3 H), 8.16–8.20 (m, 3 H),
8.70 (br s, 1 H).
13C NMR (100 MHz, CDCl3): δ = 28.9, 33.6, 96.3, 111.0, 120.5,
121.8, 122.7, 124.4, 126.6, 127.8, 129.1, 131.3, 133.4, 150.2, 162.7,
163.2.
HRMS: m/z (M+) calcd for C23H17N3O: 351.1372; found: 351.1367.
2-[2-(4-Methoxyphenyl)-1H-indol-3-yl]-5-phenyl-1,3,4-oxadia-
zole (3da)
Following the typical procedure for 3aa, the reaction was per-
formed with CuF2 (61 mg, 0.60 mmol), 1,10-phenanthroline (109
mg, 0.60 mmol), K3PO4 (191 mg, 0.90 mmol), MS 3Å (200 mg), 2-
fluoro-N-{2-[(4-methoxyphenyl)ethynyl]phenyl}benzamide (1d-
2F; 69 mg, 0.20 mmol), and 2a (88 mg, 0.60 mmol) in DMF (2.0
mL) at 65 °C for 8 h. The crude product was purified by column
chromatography on silica gel (hexane–EtOAc, 2:1, v/v) followed by
GPC to give 3da as a pale yellow powder; yield: 56 mg (0.15 mmol,
76%); mp 172–174 °C.
1H NMR (600 MHz, CDCl3): δ = 3.90 (s, 3 H), 7.05 (d, J = 8.8 Hz,
2 H), 7.26–7.37 (m, 2 H), 7.46–7.50 (m, 4 H), 7.72 (d, J = 7.9 Hz,
2 H), 7.94 (d, J = 7.9 Hz, 2 H), 7.42 (d, J = 7.0 Hz, 1 H), 8.59 (br s,
1 H).
HRMS: m/z (M+) calcd for C20H19N3O: 317.1528; found: 317.1525.
2-(5-Methyl-2-phenyl-1H-indol-3-yl)-5-phenyl-1,3,4-oxadia-
zole (3ha)
13C NMR (150 MHz, CDCl3): δ = 55.5, 97.8, 111.0, 114.0, 121.6,
122.1, 123.6, 123.7, 124.3, 126.6, 126.8, 128.9, 130.7, 131.1, 135.6,
140.4, 160.6, 162.2, 162.8.
HRMS: m/z (M+) calcd for C23H17N3O2: 367.1321; found:
367.1324.
Following the typical procedure for 3aa, but excluding the addition
of MS 3Å, the reaction was performed with CuF2 (61 mg, 0.60
mmol), 1,10-phenanthroline (109 mg, 0.60 mmol), K3PO4 (191 mg,
0.90 mmol), 2-fluoro-N-[4-methyl-2-(phenylethynyl)phenyl]benz-
amide (1h-2F; 66 mg, 0.20 mmol), and 2a (88 mg, 0.60 mmol) in
DMF (2.0 mL) at 65 °C for 8 h. The crude product was purified by
column chromatography on silica gel (hexane–EtOAc, 2:1, v/v) fol-
lowed by GPC to give 3ha as a white powder; yield: 42 mg (0.12
mmol, 60%); mp >250 °C.
1H NMR (400 MHz, CDCl3): δ = 2.55 (s, 3 H), 7.18 (d, J = 8.7 Hz,
1 H), 7.37 (d, J = 8.2 Hz, 1 H), 7.42–7.50 (m, 3 H), 7.53–7.54 (m,
3 H), 7.73–7.75 (m, 2 H), 7.85–7.87 (m, 2 H), 8.27 (s, 1 H), 8.53 (br
s, 1 H).
2-Phenyl-5-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}-
1,3,4-oxadiazole (3ea)
Following the typical procedure for 3aa, but excluding the addition
of MS 3Å, the reaction was performed with CuF2 (61 mg, 0.60
mmol), 1,10-phenanthroline (109 mg, 0.60 mmol), K3PO4 (191 mg,
0.90 mmol), 2-fluoro-N-{2-[(4-(trifluoromethyl)phenyl)ethy-
nyl]pheny}benzamide (1e-2F; 77 mg, 0.20 mmol), and 2a (88 mg,
0.60 mmol) in DMF (2.0 mL) at 65 °C for 8 h. The crude product
was purified by column chromatography on silica gel (hexane–
EtOAc, 2:1, v/v) followed by GPC to give 3ea as a pale yellow pow-
der; yield: 30 mg (0.074 mmol, 37%); mp 227–229 °C.
13C NMR (100 MHz, CDCl3): δ = 21.7, 98.0, 110.7, 121.5, 124.3,
125.5, 126.6, 126.9, 128.5, 128.9, 129.3, 129.4, 131.1, 131.7, 131.8,
134.0, 140.2, 162.1, 162.7.
HRMS: m/z (M+) calcd for C23H17N3O: 351.1372; found: 351.1372.
1H NMR (400 MHz, DMSO-d6): δ = 7.29–7.36 (m, 2 H), 7.51–7.60
(m, 4 H), 7.79 (d, J = 7.6 Hz, 2 H), 7.95 (d, J = 8.2 Hz, 2 H), 8.07
(d, J = 8.2 Hz, 2 H), 8.25 (d, J = 6.8 Hz, 1 H), 12.5 (br s, 1 H).
2-(5-Chloro-2-phenyl-1H-indol-3-yl)-5-phenyl-1,3,4-oxadia-
zole (3ia)
13C NMR (100 MHz, DMSO-d6): δ = 97.3, 112.2, 120.8, 121.8,
123.6, 123.7, 124.2 (q, J = 271 Hz), 125.1 (q, J = 4.0 Hz), 125.8,
126.1, 129.336, 129.340 (q, J = 32 Hz), 130.6, 131.6, 135.4, 136.3,
138.9, 161.6, 162.0.
HRMS: m/z (M+) calcd for C23H14F3N3O: 405.1089; found:
405.1083.
Following the typical procedure for 3aa, but excluding the addition
of MS 3Å, the reaction was performed with CuF2 (61 mg, 0.60
mmol), 1,10-phenanthroline (109 mg, 0.60 mmol), K3PO4 (191 mg,
0.90 mmol), N-[4-chloro-2-(phenylethynyl)phenyl]-2-fluorobenz-
amide (1i-2F; 70 mg, 0.20 mmol), and 2a (88 mg, 0.60 mmol) in
DMF (2.0 mL) at 65 °C for 8 h. The crude product was purified by
column chromatography on silica gel (hexane–EtOAc, 2:1, v/v) fol-
lowed by GPC to give 3ia as a pale yellow powder; yield: 13 mg
(0.035 mmol, 18%); mp >250 °C.
1H NMR (400 MHz, DMSO-d6): δ = 7.38 (dd, J = 1.8, 8.5 Hz, 1 H),
7.61–7.68 (m, 7 H), 7.82–7.85 (m, 2 H), 7.89–7.92 (m, 2 H), 8.30
(d, J = 1.8 Hz, 1 H), 12.6 (br s, 1 H).
13C NMR (100 MHz, DMSO-d6): δ = 96.1, 113.7, 119.9, 123.3,
123.6, 126.05, 126.09, 127.1, 128.4, 129.4, 129.70, 129.73, 130.8,
131.6, 134.7, 142.3, 161.4, 162.0.
2-[2-(1-Naphthyl)-1H-indol-3-yl]-5-phenyl-1,3,4-oxadiazole
(3fa)
Following the typical procedure for 3aa, but excluding the addition
of MS 3Å, the reaction was performed with CuF2 (61 mg, 0.60
mmol), 1,10-phenanthroline (109 mg, 0.60 mmol), K3PO4 (191 mg,
0.90 mmol), N-[2-(naphthylethynyl)phenyl]-2-(trifluorometh-
yl)benzamide (1f-2CF3; 83 mg, 0.20 mmol), and 2a (88 mg, 0.60
mmol) in DMF (2.0 mL) at 65 °C for 8 h. The crude product was
purified by column chromatography on silica gel (hexane–EtOAc,
2:1, v/v) followed by GPC to give 3fa as a pale yellow oil; yield: 45
mg (0.12 mmol, 58%).
HRMS: m/z (M+) calcd for C22H14ClN3O: 371.0825; found:
371.0822.
Synthesis 2012, 44, 1515–1520
© Georg Thieme Verlag Stuttgart · New York